The decrease in CarnoSyn ® beta-alanine royalty, licensing, and raw material sales revenue during the second quarter of fiscal 2025 was primarily due to a decrease in orders from existing customers.
JELD-WEN Holding, Inc. shares fell 40% after a Q3 2024 miss, downward outlook revision, and industry challenges. Click here ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback